193 related articles for article (PubMed ID: 22052412)
21. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
23. Echinocandin use in the neonatal intensive care unit.
Caudle KE; Inger AG; Butler DR; Rogers PD
Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
[TBL] [Abstract][Full Text] [Related]
24. [Micafungin: experimental therapy of fungal infections in animal models].
Javier Pastor F; Guarro J
Rev Iberoam Micol; 2009 Mar; 26(1):42-8. PubMed ID: 19463276
[TBL] [Abstract][Full Text] [Related]
25. Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.
Saraya T; Tanabe K; Araki K; Yonetani S; Makino H; Watanabe T; Tsujimoto N; Takata S; Kurai D; Ishii H; Miyazaki Y; Takizawa H; Goto H
J Clin Microbiol; 2014 Jul; 52(7):2709-12. PubMed ID: 24789192
[TBL] [Abstract][Full Text] [Related]
26. Candida glabrata--unique features and challenges in the clinical management of invasive infections.
Glöckner A; Cornely OA
Mycoses; 2015 Aug; 58(8):445-50. PubMed ID: 26207423
[TBL] [Abstract][Full Text] [Related]
27. [Micafungin for therapy of invasive candidiasis in solid organ transplant recipients].
Fortún-Abete J
Rev Iberoam Micol; 2009 Mar; 26(1):65-8. PubMed ID: 19463280
[TBL] [Abstract][Full Text] [Related]
28. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
Le A; Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584138
[TBL] [Abstract][Full Text] [Related]
29. Combined antifungal therapy in a murine infection by Candida glabrata.
Mariné M; Serena C; Pastor FJ; Guarro J
J Antimicrob Chemother; 2006 Dec; 58(6):1295-8. PubMed ID: 17012301
[TBL] [Abstract][Full Text] [Related]
30. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.
Costa-de-Oliveira S; Marcos Miranda I; Silva RM; Pinto E Silva A; Rocha R; Amorim A; Gonçalves Rodrigues A; Pina-Vaz C
Antimicrob Agents Chemother; 2011 Mar; 55(3):1312-4. PubMed ID: 21149621
[TBL] [Abstract][Full Text] [Related]
31. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.
Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323
[TBL] [Abstract][Full Text] [Related]
32. Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
Oliveira ER; Fothergill A; Kirkpatrick WR; Patterson TF; Redding SW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Apr; 105(4):457-9. PubMed ID: 18329581
[TBL] [Abstract][Full Text] [Related]
33. Micafungin: new drug. Severe candidiasis: a third echinocandin, with life-threatening hepatotoxicity.
Prescrire Int; 2009 Aug; 18(102):154. PubMed ID: 19743568
[No Abstract] [Full Text] [Related]
34. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine.
Dumaine V; Eyrolle L; Baixench MT; Paugam A; Larousserie F; Padoin C; Tod M; Salmon D
Int J Antimicrob Agents; 2008 Apr; 31(4):398-9. PubMed ID: 18242959
[No Abstract] [Full Text] [Related]
35. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
36. [Micafungin for the treatment of neonatal invasive candidiasis].
Infante-López ME; Rojo-Conejo P
Rev Iberoam Micol; 2009 Mar; 26(1):56-61. PubMed ID: 19463278
[TBL] [Abstract][Full Text] [Related]
37. Breakthrough disseminated cryptococcosis during micafungin therapy.
Lee WS; Hsieh TC; Ou TY; Teng SO; Chen FL; Wang FD
J Microbiol Immunol Infect; 2015 Aug; 48(4):456-8. PubMed ID: 23632603
[TBL] [Abstract][Full Text] [Related]
38. Caspofungin as treatment for Candida glabrata hip infection.
Lejko-Zupanc T; Mozina E; Vrevc F
Int J Antimicrob Agents; 2005 Mar; 25(3):273-4. PubMed ID: 15737527
[No Abstract] [Full Text] [Related]
39. Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis.
Charlier C; El Sissy C; Bachelier-Bassi S; Scemla A; Quesne G; Sitterlé E; Legendre C; Lortholary O; Bougnoux ME
Antimicrob Agents Chemother; 2016 Jan; 60(1):662-5. PubMed ID: 26525799
[TBL] [Abstract][Full Text] [Related]
40. Endocarditis caused by Candida dubliniensis.
Garcia J; Soch K; Matthew E; Surani S; Horseman MA
Am J Med Sci; 2013 Sep; 346(3):237-9. PubMed ID: 23974269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
